Abstract:BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmacogenetics in clinical practice is the genetic test for HLA-B*5701 in patients who are going to start treatment with abacavir, due to its relationship with the hypersensitivity reaction it produces.Other adverse reactions of this type are: Relationship HLA-B15.02 with Steven-Johnson Syndrome and toxic epidermal necrolysis by carbamazepine, relationship HLA-B58.01 with Hypersensitivity Syndrome, Steven Johnson Syndrome and toxic epidermal necrolysis by allopurinol, relationship HLA-B35 with skin eruption by nevirapine and relationship HLA-B13.01 with hypersensitivity reaction induced by dapsone (DIHR).The objective of the study is to determine the prevalence of the HLA-B57.01 allele and the HLA-B35.05,HLA-B58.01,HLA-B15.02 and HLA-B13.01 alleles associated with adverse drug reactions in our healthcare area. METHODSDescriptive observational study of patients with HIV diagnosis, with request for genotyping HLA-B57.01 in our hospital area between July 2016 and September 2019 They were a total of 613 patients.Maxwell® 16 System, Blood DNA Purification System, was used to isolate the DNA in an automated way, which was later amplified by PCR.A strip probe assay, INNO-LiPAHLA-B Update Plus, was then used to determine the molecular typing of human leukocyte antigen (HLA) B alleles.The results were analyzed using Excel. RESULTSTo determine the prevalence of HLA-B alleles, an Excel database was created with a total of 613 samples.A prevalence of 3.75% was found for the HLA B57.01 allele.The prevalences of the other alleles with their respective confidence intervals (IC95%) and number of patients are detailed below: HLA-B 57.01 3,75% (2,51-5,57) 23 patients, HLA-B 58 0,82% (0,35-1,89) 5 patients, HLA-B35 9,79% (7,68-12,40) 60 patients, HLA-B15 1,14% (0,55-2,34) 7 patients and HLA-B13 1,63% (0,89-2,98) 10 patients. CONCLUSIONSThe calculated prevalences are lower than those described by other studies, such as the PREDICT-1 study with the participation of 15 European countries.We also found a high prevalence of the HLA-B35 allele, associated with adverse reactions to Nevirapine, more particularly the skin eruption induced by this second line antiretroviral in Spain.This high prevalence of HLA-B alleles associated with drug intolerance in our HIV population suggests that the determination of these alleles may be of great importance and utility in routine clinical practice in the at-risk population.

Peptide Binding Specificities of Hla-B5701 and B5801

Presence of Valine at Position 27 of the Hepatitis B Virus Core Gene is Associated with Severe Liver Inflammation in Chinese Patients

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

The Rigidity of a Structural Bridge on HLA-I Binding Groove Explains Its Differential Outcome in Cancer Immune Response.

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

Associations Between Human Leukocyte Antigen Polymorphisms and Hypersensitivity to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus: a Meta-Analysis.

Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules

HLA class I peptide polymorphisms contribute to class II DQβ0603:DQα0103 antibody specificity

Structural and Energetic Insights into the Intermolecular Interaction among Human Leukocyte Antigens, Clinical Hypersensitive Drugs and Antigenic Peptides

Toxicology, Including Therapeutic Drug Monitoring

Peptide binding motifs and specificities for HLA-DQ molecules

Update on HLA-B*15:02 allele associated with adverse drug reactions

Analysis of Antigen Motifs Presented by HLA-B27 Using Combinatorial Peptide Libraries

Erratum To: Studies on Abacavir-Induced Hypersensitivity Reaction: a Successful Example of Translation of Pharmacogenetics to Personalized Medicine

Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia

Characterization of Amino Acid Residues of T-cell Receptors Interacting with HLA-A*02-restricted Antigen Peptides

Specific amino acid patterns define split specificities of HLA-B15 antigens enabling conversion from DNA-based typing to serological equivalents

Purification, Crystallization and Crystallographic Analysis of HLA-B*15:02 Complexed with an Endogenous Peptide

994 Risk and Association of HLA Alleles with Methimazole Induced Cutaneous Adverse Reactions in Chinese Han Population

Related parameters of affinity and stability prediction of HLA-A*2402 restricted antigen peptides based on molecular docking

Characteristics of Amino Acid Substitutions Within the "a" Determinant Region of Hepatitis B Virus in Chronically Infected Patients with Coexisting HBsAg and Anti-Hbs.

Peptide Binding Specificities of Hla-B*5701 and B*5801